Q-omics provides the consensus-scored H2BC2P profile across patient tissues and cancer cell-line models. H2BC2P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, H2BC2P is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, H2BC2P RNA expression shows 5,892 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight UCS, LIHC, and KIRC as cancer lineages where H2BC2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2BC2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2BC2P survival associations across molecular data types. H2BC2P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2BC2P RNA expression–survival associations across cancer types. High H2BC2P expression shows unfavorable associations in UCS, ACC, STAD, BLCA, COAD and LAML. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify UCS as the clearest survival context for H2BC2P RNA expression.
This table summarizes H2BC2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for H2BC2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2BC2P shows higher tumor expression in LIHC. The LIHC box plot shows higher H2BC2P RNA expression in tumor versus normal tissue (log2 FC = +0.093, t-test p = .022).
This table shows molecular features associated with H2BC2P in patient tissues and cancer cell lines. In patient samples, H2BC2P shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
